FierceBiotechOriginal article
{"a":[{"_":"InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test","$":{"href":"/biotech/innocares-oral-tyk2-inhibitor-races-psoriasis-treatment-finish-line","hreflang":"en"}}]}
Phase 3positivefadeucravacitinibPositive
AI Analysis
Summary
InnoCare Pharma announced that its oral TYK2 inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial for moderate-to-severe plaque psoriasis. This positive trial result represents a key milestone for the drug's development.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met primary endpoint in phase 3 trial
Importance:7/10
Sentiment:
0.85
Phase 3psoriasisTYK2 inhibitororal medicationpositive trial data
Related Companies
Read the original article
Published by FierceBiotech on July 27, 2026 10:10 AM